Science
Revolutionizing delivery
across the blood-brain barrier.
Our Platform: TRACER
Reaching CNS targets once thought unreachable.
Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs).
Non-Viral Approaches
Multiple modalities to treat neurological diseases.
Recent Publications & Presentations
Clinical Trials on Alzheimer’s Disease 2025:
Oral Presentation: Results of a Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single IV Doses of VY7523, a Tau-Targeting Therapeutic, in Healthy Adult Participants
Society for Neuroscience – Neuroscience 2025:
Intravenous Delivery of a Bi-Functional AAV Gene Therapy to Reduce Endogenous ApoE4 and Express ApoE2 in ApoE4 Humanized Mice
Molecular Therapy:
Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier
Our Pipeline
Partnerships
Our allies in realizing the potential of neuro-genetic medicines
